What Aclaris Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 1 |
| Total trades | 2 | 39 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 36,375 | 560,155 |
| Disposed | 12,385 | 445,821 |
| Net activity | +23,990 | +114,334 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Kolbeck Roland Wilhelm | Chief Scientific Officer | Aug 01 | Withheld — tax / exercise cost · F | −12,385 | $5.20 | −$64.4K | 23,990 |
| Kolbeck Roland Wilhelm | Chief Scientific Officer | Aug 01 | Exercise / conversion · M | +36,375 | — | — | 36,375 |
| Schiff Dr Drew | Director | Jun 05 | Exercise / conversion · M | +11,580 | — | — | 25,540 |
| Milano Vincent | Director | Jun 05 | Exercise / conversion · M | +11,580 | — | — | 28,896 |
| Gowen Maxine | Director | Jun 05 | Exercise / conversion · M | +11,580 | — | — | 33,334 |
| Mehra Anand | Director | Jun 05 | Exercise / conversion · M | +11,580 | — | — | 726,403 |
| Molineaux Christopher P. | Director | Jun 05 | Exercise / conversion · M | +11,580 | — | — | 69,536 |
| Humphries William D. | Director | Jun 05 | Exercise / conversion · M | +11,580 | — | — | 45,105 |
| Hall Jesse Wayne | Chief Medical Officer | May 01 | Withheld — tax / exercise cost · F | −9,330 | $4.41 | −$41.1K | 27,045 |
| Hall Jesse Wayne | Chief Medical Officer | May 01 | Exercise / conversion · M | +36,375 | — | — | 36,375 |
| Leonard Braden Michael | 10% owner | Apr 23 | Open-market sale · S | −300,000 | $4.53 | −$1.36M | 13,950,000 |
| Balthaser Kevin | Chief Financial Officer | Mar 01 | Withheld — tax / exercise cost · F | −677 | $2.87 | −$1.94K | 187,453 |
| Balthaser Kevin | Chief Financial Officer | Mar 01 | Exercise / conversion · M | +2,375 | — | — | 188,130 |
| Balthaser Kevin | Chief Financial Officer | Feb 03 | Withheld — tax / exercise cost · F | −6,449 | $3.47 | −$22.4K | 185,755 |
| Balthaser Kevin | Chief Financial Officer | Feb 03 | Exercise / conversion · M | +22,025 | — | — | 192,204 |
| Loerop James | Chief Business Officer | Feb 03 | Withheld — tax / exercise cost · F | −5,937 | $3.47 | −$20.6K | 192,260 |
| Loerop James | Chief Business Officer | Feb 03 | Exercise / conversion · M | +20,875 | — | — | 198,197 |
| Davis Hugh M. | President and COO | Feb 03 | Exercise / conversion · M | +18,675 | — | — | 45,425 |
| Walker Neal | CEO | Feb 03 | Withheld — tax / exercise cost · F | −18,611 | $3.47 | −$64.6K | 1,543,886 |
| Walker Neal | CEO | Feb 03 | Exercise / conversion · M | +63,475 | — | — | 1,562,497 |
Loading...
